Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

884
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
884
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

512
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
512
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

604
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
604
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

762
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
762
Angina IV: Management01:26

Angina IV: Management

470
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

YAP1 and QSER1 are key modulators of embryonic signaling pathways in the mammalian epiblast.

EMBO reports·2026
Same author

Coronary Artery Calcium as a Biological Staging Marker for Atherosclerosis: Aligning Preventive Therapies With Plaque Evolution.

Cardiology in review·2026
Same author

Distinct worldviews determine how meat producers navigate competing sustainability priorities in the United States.

Nature food·2026
Same author

Albuminuria in Heart Failure: From Marker to Modifiable Target.

Cardiology in review·2025
Same author

How Do We Know What We Know About Consumer Attitudes Towards Meat Sustainability? A Scoping Review of Studies Published Globally Between 2010-2022.

Current environmental health reports·2025
Same author

Beyond Diursesis: Rethinking Fluid and Sodium Strategies in Heart Failure.

Cardiology in review·2025

Related Experiment Video

Updated: Apr 22, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.3K

Postmyocardial Infarction Depression as a Modifiable Secondary Prevention Risk Factor.

Amogh Jyothi Arun1, Elizabeth Abraham1, Madiha Baig1

  • 1From the School of Medicine, New York Medical College, Valhalla, NY.

Cardiology in Review
|April 20, 2026
PubMed
Summary

Major depressive disorder following myocardial infarction (MI) significantly increases mortality risk. Effective depression management and integrated care are crucial for improving patient outcomes and cardiovascular recovery.

Keywords:
brain–heart axiscardiac rehabilitationcardiovascular outcomesdepressionmyocardial infarctionsecondary prevention

More Related Videos

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

9.4K
Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
08:41

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction

Published on: January 12, 2016

15.4K

Related Experiment Videos

Last Updated: Apr 22, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

22.3K
A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

9.4K
Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
08:41

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction

Published on: January 12, 2016

15.4K

Area of Science:

  • Cardiology
  • Psychiatry
  • Neuroscience

Background:

  • Major depressive disorder (MDD) affects ~25% of myocardial infarction (MI) survivors, significantly higher than the general population.
  • Post-MI depression independently predicts mortality, recurrent ischemic events, and hospital readmissions, with risk escalating with symptom severity.
  • A bidirectional brain-heart axis links depression to adverse cardiovascular outcomes via mechanisms like autonomic dysregulation and inflammation.

Purpose of the Study:

  • To review the impact of post-MI depression on cardiovascular outcomes.
  • To explore treatment strategies and the role of cardiac rehabilitation.
  • To advocate for integrating depression management into secondary prevention.

Main Methods:

  • Literature review of studies on post-MI depression, its cardiovascular impact, and treatment.
  • Analysis of evidence regarding the brain-heart axis and therapeutic interventions.
  • Examination of the role of cardiac rehabilitation and integrated care models.

Main Results:

  • Treatment of post-MI depression improves symptoms and quality of life; SSRIs show potential safety and benefit in cardiac patients.
  • Limited randomized evidence exists for definitive reductions in mortality or major adverse cardiovascular events.
  • Untreated depression correlates with worse outcomes, highlighting the need for durable remission.
  • Cardiac rehabilitation aids recovery and reduces depression, but depression hinders participation.

Conclusions:

  • Post-MI depression is a critical, modifiable risk factor requiring systematic integration into cardiovascular care.
  • Collaborative care models, stepped-care treatment, and longitudinal screening are vital for enhancing both psychological and cardiovascular health.
  • Reframing depression as a secondary prevention target is essential for comprehensive patient management.